This invention is a family of small-molecule derivatives of the diuretic bumetanide that block the NKCC1 ion transporter, which drives swelling and injury in the brain after stroke. In mouse stroke models, the lead compound (STS66) reduced brain damage and swelling, improved survival and restored sensorimotor function better than bumetanide itself.
Description
Unmet Need - Bumetanide is poorly suited to treating brain injury because it barely crosses into the brain and has a strong diuretic effect. These derivatives were designed to target NKCC1 for neuroprotection and showed better outcomes than bumetanide in mouse stroke models.
Following a stroke, the NKCC1 transporter moves sodium, potassium and chloride into brain cells. This contributes to cell swelling, brain edema and loss of function. The invention modifies the bumetanide structure to produce more lipophilic compounds that retain NKCC1 inhibition. The lead compound, STS66, is a bumetanide analog in which the carboxylic acid is replaced by a trifluoroethylamino-methyl group. The change is intended to improve penetration, metabolic stability and therapeutic effectiveness. The same scaffold supports related analogs, including amide and benzyl-substituted variants.
The compounds were tested in transient and permanent stroke models in mice, including mice made hypertensive. In cell studies they also inhibited potassium (rubidium) uptake and proliferation in glioma cells.
Applications
- Acute ischemic stroke therapy to limit infarct size and cerebral edema
- Post-stroke neurorehabilitation to speed recovery of motor and sensory function
- Stroke treatment in hypertensive patients, who make up most stroke cases
- Traumatic brain injury, spinal cord injury and peripheral nerve injury
- Glioma, as a standalone or adjunct therapy
Advantages
- Smaller brain infarct and less cerebral swelling than vehicle in mouse stroke models
- Survival was 100% in the STS66 group in the transient stroke model, versus about 33% mortality in vehicle-treated mice
- Faster and more complete recovery of neurological, motor and sensorimotor function than bumetanide
- Reduced infarct volume and edema in a hypertensive stroke model, where bumetanide showed no significant benefit
- A small-molecule scaffold with multiple analogs, suited to conventional drug development and routes such as oral, topical and parenteral
Invention Readiness
Lead compounds have been synthesized and characterized. Efficacy has been shown in vivo in mouse models of transient and permanent stroke, including a hypertensive model. Lead compounds have been synthesized and characterized. Efficacy has been shown in vivo in mouse models of transient and permanent stroke, including a hypertensive model.
IP Status
https://patents.google.com/patent/US20260132103A1Related Publication(s)
Luo, L., Wang, J., Ding, D., Hasan, M. N., Yang, S.-S., Lin, S.-H., Schreppel, P., Sun, B., Yin, Y., Erker, T., & Sun, D. (2020). Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66. Frontiers in Physiology, 11. https://doi.org/10.3389/fphys.2020.00911
Huang, H., Bhuiyan, M. I. H., Jiang, T., Song, S., Shankar, S., Taheri, T., Li, E., Schreppel, P., Hintersteininger, M., Yang, S.-S., Lin, S.-H., Molyneaux, B. J., Zhang, Z., Erker, T., & Sun, D. (2019). A Novel Na + -K + -Cl − Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke. Stroke, 50(4), 1021–1025. https://doi.org/10.1161/strokeaha.118.024287